Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Acute Leukemia AML: AML:

AML randomized trials

 
Nigel Russell, Sylvie Freeman, Charlotte Wilhelm-Benartzi, et al.
 
The authors of the abstract conclude: 
This study found no evidence of benefit from a fractionated dose of GO when given in course 1 of induction. DAGO1 and DAGO2 gave similar outcomes with equivalent toxicity. Compared to AML16, the outcome has improved for MRD+ve patients; this may reflect treatment intensification post course 1.
————————————————————————————————————————————————————————
 
 
Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, et al.
 
The authors of the abstract conclude: 
VEN+LDAC demonstrates a clinically meaningful improvement in OS compared with PBO+LDAC, with a tolerable and manageable safety profile. These data support VEN+LDAC as a frontline treatment option for older pts with AML, as well as those considered unfit for intensive chemotherapy.
————————————————————————————————————————————————————————
 
 
Mike Dennis, Ian Thomas, Cono Ariti, et al.
 
The authors of the abstract conclude: 
The addition of AC220 to LDAC did not improve survival in all patients with AML. This is however the first randomised study to demonstrate that elderly FLT3-ITD AML patients appear to have both improved response and survival with TKI addition to low dose chemotherapy. AC220 was well tolerated with an acceptable toxicity profile. Further evaluation of AC220 combination strategies in FLT3-ITD AML continue.
————————————————————————————————————————————————————————
 
 
Michael Lübbert, Olga Grishina, Claudia Schmoor, et al.
 
The authors of the abstract conclude: 
The addition of ATRA, but not VPA, to DAC improved the response rate and, particularly overall survival. The latter thus appears to be mediated by a delay of secondary resistance development. A better understanding of the underlying mechanism of action of this in vivo synergism between an HMA and ATRA is needed, particularly as regards modulation of HMA resistance development.
————————————————————————————————————————————————————————
 
 
Courtney DiNardo, Andre Schuh, Eytan Stein, et al. 
 
The authors of the abstract conclude: 
Combination ENA + AZA resulted in significantly improved response rates vs. AZA monotherapy and was generally well-tolerated in pts with mIDH2 ND-AML. ENA + AZA also led to deep reductions in 2-HG concentrations and mIDH2 VAF vs. AZA Only. Median OS in the AZA Only arm was longer than previous reports of AZA in pts with mIDH2 ND-AML. The impact of subsequent Tx on OS and EFS, and new translational data, will be presented at the meeting.